|
Shanghai Raas Blood Products Co., Ltd. (002252.sz) Avaliação DCF
CN | Healthcare | Biotechnology | SHZ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) Bundle
Descubra o verdadeiro potencial da Shanghai Raas Blood Products Co., Ltd. (002252SZ) com nossa calculadora DCF de primeira linha! Ajuste as principais suposições, explore vários cenários e examine como diferentes mudanças afetam a avaliação da Shanghai Raas Blood Products Co., Ltd. (002252SZ) - tudo dentro de um único modelo do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,585.0 | 2,761.7 | 4,287.7 | 6,567.2 | 7,964.0 | 8,010.0 | 8,056.2 | 8,102.8 | 8,149.6 | 8,196.6 |
| Revenue Growth, % | 0 | 6.84 | 55.26 | 53.16 | 21.27 | 0.57759 | 0.57759 | 0.57759 | 0.57759 | 0.57759 |
| EBITDA | 885.1 | 1,630.4 | 1,302.2 | 2,458.6 | 2,367.2 | 3,056.7 | 3,074.4 | 3,092.1 | 3,110.0 | 3,128.0 |
| EBITDA, % | 34.24 | 59.04 | 30.37 | 37.44 | 29.72 | 38.16 | 38.16 | 38.16 | 38.16 | 38.16 |
| Depreciation | 154.8 | 161.5 | 168.6 | 194.5 | 163.0 | 332.8 | 334.7 | 336.7 | 338.6 | 340.6 |
| Depreciation, % | 5.99 | 5.85 | 3.93 | 2.96 | 2.05 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 |
| EBIT | 730.3 | 1,468.9 | 1,133.6 | 2,264.1 | 2,204.2 | 2,723.9 | 2,739.7 | 2,755.5 | 2,771.4 | 2,787.4 |
| EBIT, % | 28.25 | 53.19 | 26.44 | 34.48 | 27.68 | 34.01 | 34.01 | 34.01 | 34.01 | 34.01 |
| Total Cash | 1,731.8 | 2,213.4 | 2,965.0 | 4,215.2 | 4,198.3 | 5,337.7 | 5,368.5 | 5,399.6 | 5,430.7 | 5,462.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 867.8 | 580.2 | 649.5 | 915.4 | 774.1 | 1,496.1 | 1,504.7 | 1,513.4 | 1,522.2 | 1,530.9 |
| Account Receivables, % | 33.57 | 21.01 | 15.15 | 13.94 | 9.72 | 18.68 | 18.68 | 18.68 | 18.68 | 18.68 |
| Inventories | 1,913.2 | 2,163.1 | 3,173.2 | 3,268.8 | 3,666.9 | 5,161.1 | 5,190.9 | 5,220.9 | 5,251.0 | 5,281.4 |
| Inventories, % | 74.01 | 78.33 | 74.01 | 49.78 | 46.04 | 64.43 | 64.43 | 64.43 | 64.43 | 64.43 |
| Accounts Payable | 52.7 | 97.1 | 966.1 | 1,137.7 | 1,650.8 | 1,059.5 | 1,065.7 | 1,071.8 | 1,078.0 | 1,084.2 |
| Accounts Payable, % | 2.04 | 3.52 | 22.53 | 17.32 | 20.73 | 13.23 | 13.23 | 13.23 | 13.23 | 13.23 |
| Capital Expenditure | -154.8 | -251.8 | -204.6 | -225.7 | -450.8 | -464.2 | -466.9 | -469.6 | -472.3 | -475.0 |
| Capital Expenditure, % | -5.99 | -9.12 | -4.77 | -3.44 | -5.66 | -5.8 | -5.8 | -5.8 | -5.8 | -5.8 |
| Tax Rate, % | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 | 19.26 |
| EBITAT | 605.6 | 1,316.3 | 953.5 | 1,872.2 | 1,779.6 | 2,288.4 | 2,301.7 | 2,314.9 | 2,328.3 | 2,341.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -2,122.8 | 1,308.1 | 707.0 | 1,651.1 | 1,748.2 | -650.4 | 2,137.2 | 2,149.5 | 2,161.9 | 2,174.4 |
| WACC, % | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 6,232.4 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | 2,251 | |||||||||
| Terminal Value | 65,999 | |||||||||
| Present Terminal Value | 47,255 | |||||||||
| Enterprise Value | 53,487 | |||||||||
| Net Debt | -3,999 | |||||||||
| Equity Value | 57,486 | |||||||||
| Diluted Shares Outstanding, MM | 6,591 | |||||||||
| Equity Value Per Share | 8.72 |
What You Will Receive
- Authentic 002252 Financial Data: Pre-populated with Shanghai RAAS Blood Products Co., Ltd.'s historical and projected figures for accurate analysis.
- Completely Customizable Template: Easily adjust key metrics such as revenue growth, WACC, and EBITDA percentage.
- Instant Calculations: Watch the intrinsic value of 002252 update in real-time as you make adjustments.
- Expert Valuation Tool: Tailored for investors, analysts, and consultants pursuing precise DCF results.
- Intuitive Design: Streamlined layout with straightforward instructions suitable for all levels of experience.
Key Features
- 🔍 Real-Life Shanghai RAAS Financials: Pre-filled historical and projected data for Shanghai RAAS Blood Products Co., Ltd. (002252SZ).
- ✏️ Fully Customizable Inputs: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Integrated formulas calculate the intrinsic value of Shanghai RAAS using the Discounted Cash Flow method.
- ⚡ Instant Results: Immediately visualize the valuation of Shanghai RAAS after making adjustments.
- Scenario Analysis: Explore and compare various financial assumptions with side-by-side outcomes.
How It Works
- Step 1: Download the Excel file.
- Step 2: Examine the pre-filled data for Shanghai RAAS Blood Products Co., Ltd. (002252SZ), including historical and forecasted figures.
- Step 3: Modify the key assumptions (yellow cells) according to your analysis.
- Step 4: Observe the automatic updates reflecting the intrinsic value of Shanghai RAAS Blood Products Co., Ltd. (002252SZ).
- Step 5: Utilize the results for investment strategies or reporting purposes.
Why Opt for This Calculator?
- Precise Data: Authentic financials from Shanghai RAAS Blood Products Co., Ltd. ensure trustworthy valuation outcomes.
- Customizable Options: Modify key metrics such as growth rates, WACC, and tax rates to align with your forecasts.
- Efficiency Boost: Pre-configured calculations save you from starting from scratch.
- Professional Tool: Tailored for investors, analysts, and consultants in the field.
- User-Friendly Interface: Designed with an intuitive layout and clear instructions for ease of use.
Who Can Benefit from This Product?
- Institutional Investors: Develop comprehensive and trustworthy valuation models for analyzing investments in Shanghai RAAS Blood Products Co., Ltd. (002252SZ).
- Corporate Finance Departments: Evaluate valuation scenarios to inform and refine strategic decisions within their organizations.
- Financial Consultants and Advisors: Deliver precise valuation insights to clients interested in shares of Shanghai RAAS Blood Products Co., Ltd. (002252SZ).
- Academic Researchers and Students: Utilize real-world financial data to practice and enhance skills in financial modeling.
- Biotech Enthusiasts: Gain insights into how companies like Shanghai RAAS Blood Products Co., Ltd. (002252SZ) are valued within the biotechnology sector.
What the Template Includes
- Detailed DCF Model: Editable template featuring thorough valuation calculations.
- Industry-Specific Data: Shanghai RAAS Blood Products Co., Ltd.'s historical and projected financials preloaded for in-depth analysis.
- Adjustable Variables: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Comprehensive Financial Statements: Complete annual and quarterly reports for deeper understanding.
- Essential Ratios: Integrated analysis for assessing profitability, efficiency, and leverage.
- Visual Dashboard: Graphs and tables providing clear and actionable insights.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.